Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Cancer Biomarkers Licenses Chinese Rights to Colorectal Cancer Tests

NEW YORK (GenomeWeb) – Oxford Cancer Biomarkers (OCB) announced today that it has licensed its suite of in vitro colorectal cancer diagnostics to Chinese precision medicine firm My-BioMed Biotechnology (MBM).

Under the terms of the deal, MBM will have access to OCB's ColoTox, ColoProg, and ColoPredict tests and technologies, which will be offered in China through a purpose-built biomedical laboratory. Additional terms were not disclosed.

ColoTox is designed to predict a patient's risk of life-threatening toxicity from fluoropyrimidine-based chemotherapy by analyzing germline DNA for the presence of risk alleles. ColoProg is performed after colorectal cancer surgery to stratify a patient's risk for relapse based on various genetic biomarkers, and ColoPredict identifies healthy individuals at increased risk for developing colorectal cancer by analyzing DNA collected from a mouth swab.

"We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population," OCB Chief Medical Officer David Kerr said in a statement. "This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.